Professor of Obstetrics and Gynecology, University Tex Houston
Obstetrics & Gynecology
Dr. David M. Gershenson, MD
|
|
Give Review
David M. Gershenson works in the field of Obstetrics & Gynecology. He researched medicine at Vanderbilt University School of Medicine. He received 6 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Fellow (FACS)", "Super Doctor" and "Fellow (FACOG)". David Gershenson is a published doctor and has 101 publications published. The lastest was: 'Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer.' He accepts all Medicare patients.
Publications
- Impact of mutational Status on survival in low-grade serous carcinoma of the ovary or peritoneum.
- Small cell Carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
- Is adjuvant chemotherapy indicated in Ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.
- Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma.
- Updates and emerging therapies for rare epithelial ovarian Cancers: One size no longer fits all.
- The role of secondary cytoreduction in low-grade serous ovarian Cancer or peritoneal Cancer.
- Stage IIIC Ovarian/Peritoneal Serous Carcinoma: A Heterogeneous Group of Patients With Different Prognoses.
- Utility of (18)F-FDG PET/CT in follow-up of patients with low-grade serous Carcinoma of the ovary.
- The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian Carcinoma: A Gynecologic Oncology Group study.
- KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous Carcinoma.
- Ovarian Cancer, version 2.2013.
- Efficacy and safety of bevacizumab in recurrent sex cord-stromal Ovarian tumors: Results of a Phase 2 Trial of the Gynecologic Oncology Group.
- Poor survival with wild-type TP53 ovarian Cancer?
- KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous Carcinoma.
- Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Synd...
- CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer.
- Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies.
- PAX2 Expression in Ovarian Cancer.
- Selumetinib in women with recurrent low-grade serous Carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
- RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.
- Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian Cancer cells through induction of apoptosis and downregulation of histon...
- Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous Carcinoma of the ovary, peritoneum, or fallopian tube.
- Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary.
- Hormonal therapy for recurrent low-grade serous Carcinoma of the ovary or peritoneum.
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian Cancer.
- Proceedings from the 9th International Conference on Ovarian Cancer.
- Reclassification of serous ovarian Carcinoma by a 2-tier system: A Gynecologic Oncology Group Study.
- The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian Carcinoma.
- The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer.
- Preoperative Factors Predicting Survival After Secondary Cytoreduction for Recurrent Ovarian Cancer.
- Improved survival in non-Ashkenazi Jewish ovarian Cancer patients with BRCA1 and BRCA2 gene mutations.
- The future of gynecologic oncology: Are we headed for super-specialization?
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithe...
- Prospective evaluation of insulin resistance among endometrial Cancer patients.
- Low-grade serous primary peritoneal Carcinoma.
- Microscopic and early-stage ovarian Cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
- Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian Carcinoma.
- Is low-grade serous ovarian Cancer part of the tumor spectrum of hereditary breast and ovarian Cancer?
- Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial Cancer.
- Targeting aldehyde dehydrogenase Cancer stem cells in ovarian Cancer.
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial Carcinoma.
- BRAF mutation is rare in advanced-stage low-grade ovarian serous Carcinomas.
- Prevalence of lymph node metastasis in primary mucinous Carcinoma of the ovary.
- Unmasking the complexities of mucinous ovarian Carcinoma.
- Evaluating women with ovarian Cancer for BRCA1 and BRCA2 mutations: missed opportunities.
- Plasma cell-free DNA in ovarian Cancer: an independent prognostic biomarker.
- The heterogeneity of epithelial ovarian Cancer: getting it right.
- Healthcare reform: it's time.
- Node-positive adenoCarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
- Anti-angiogenesis therapy with bevacizumab for patients with Ovarian granulosa cell tumors.
- PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous Carcinomas.
- Anti-angiogenic properties of metronomic topotecan in ovarian Carcinoma.
- Recurrent low-grade serous ovarian Carcinoma is relatively chemoresistant.
- A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal Cancer.
- Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?
- Letter from Houston "So what part of 'stable disease' do you not understand?".
- Low-grade serous ovarian Cancer: a unique disease.
- Limited public knowledge of obesity and endometrial Cancer risk: what women know.
- SEER data: perspective at 10,000 feet.
- Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade Cancer of the ovary or peritoneum.
- HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian Carcinoma.
- Impact of vessel maturation on antiangiogenic therapy in ovarian Cancer.
- Neoadjuvant chemotherapy for low-grade serous Carcinoma of the ovary or peritoneum.
- Classification of ovarian Cancer: a genomic analysis.
- Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian Cancer.
- Clinical and biological significance of vascular endothelial growth factor in endometrial Cancer.
- Fallopian tube Cancer: stepchild or mother?
- Prospective determination of prevalence of lynch syndrome in young women with endometrial Cancer.
- Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced Ovarian, tubal, and perito...
- Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous Carcinoma as revealed by immunohistochemical analysis.
- Antitumor and antivascular effects of AVE8062 in ovarian Carcinoma.
- STK15 F31I polymorphism is associated with increased uterine Cancer risk: a pilot study.
- Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian Cancer patients.
- Management of Ovarian germ cell tumors.
- Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian Cancer.
- Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous Carcinoma of the ovary with that of serous ovarian tumors of low malignant potenti...
- Curcumin inhibits tumor growth and angiogenesis in ovarian Carcinoma by targeting the nuclear factor-kappaB pathway.
- A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
- Lack of effective systemic therapy for recurrent clear cell Carcinoma of the ovary.
- Integrating the Gynecologic Oncology Group and Gynecologic Cancer SPOREs--a square peg in a round hole or fits like a glove?
- Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
- Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian Carcinoma.
- Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian Cancer.
- Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial Cancer.
- Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian Cancer.
- Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian Cancer.
- The recurrence and the overall survival rates of Ovarian serous borderline neoplasms with noninvasive implants is time dependent.
- Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian Carcinoma.
- Analysis of EphA2 expression and mutant p53 in ovarian Carcinoma.
- The BRK tyrosine kinase is expressed in high-grade serous Carcinoma of the ovary.
- Antiangiogenic and antitumor effects of SRC inhibition in ovarian Carcinoma.
- Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
- Quantification of total plasma cell-free DNA in ovarian Cancer using real-time PCR.
- A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal Cancer.
- Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian Carcinoma therapy.
- Clinical behavior of stage II-IV low-grade serous Carcinoma of the ovary.
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian Carcinoma.
- Association between adiponectin, insulin resistance, and endometrial Cancer.
- Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for Cervical cancer.
- Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian Cancer.
Schools
Vanderbilt University
University Ia Hosps
Yale New Haven Hospital
MD Anderson Hospital
Procedures Preformed
- Colposcopy
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Gynecologic Cancer Screening
- Hysterectomy - Open
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FACS)
- Super Doctor
- Fellow (FACOG)
Education
-
University of Texas Health Science Center -
Yale-New Haven Hospital -
University of Iowa Hospitals and Clinics -
Vanderbilt University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1477651099 | |
| NPPES Provider LastName | GERSHENSON | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 11.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477651099 |
| Last Name Of The Provider | GERSHENSON |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Barry S. Siller, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Pinky F. Ronen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael J. Piegari, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Betty J. Edwards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pamela T. Soliman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Candice O. Perfetto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd M. Holt, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Traci Desplinter, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Deya J. Dafashy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro T. Ramirez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chin H. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Lu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judith K. Wolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathleen G. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dirk Kieback, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eleazar E. Soto, MD
This Doctor is OpenDoctor Recommended.
|